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Andreas Tosstorff1, Wolfgang Zaremba5, Gerhard Winter1, Stefan Zahler  4 & 
Wolfgang Friess1
A synthetic derivative, GnRH [6-D-Phe], stable against enzymatic degradation, self-assembles and 
forms nanostructures and fibrils upon a pH shift in the presence of different concentrations of Zn2+ in 
vitro. Attenuated Total Reflection Fourier Transform Infrared spectroscopy (ATR–FTIR) revealed the 
existence of higher order assembly of Zn2+: GnRH [6-D-Phe]. Nuclear Magnetic Resonance spectroscopy 
(NMR) indicated a weak interaction between Zn2+ and GnRH [6-D-Phe]. Atomic Force Microscopy (AFM) 
showed the existence of GnRH [6-D-Phe] oligomers and fibrils. Molecular Dynamic (MD) simulation 
of the 10:1 Zn2+: GnRH [6-D-Phe] explored the interaction and dimerization processes. In contrast to 
already existing short peptide fibrils, GnRH [6-D-Phe] nanostructures and fibrils form in a Tris-buffered 
pH environment in a controlled manner through a temperature reduction and a pH shift. The lyophilized 
Zn2+: GnRH [6-D-Phe] assembly was tested as a platform for the sustained delivery of GnRH [6-D-Phe] 
and incorporated into two different oil vehicle matrices. The in vitro release was slow and continuous 
over 14 days and not influenced by the oil matrix.
A non-covalent complexation of peptides with metal ions controlling their release is a method, which resembles 
their storage in vesicles at physiological conditions. Insulin, for instance, is a prominent example for a peptide 
stored in the pancreas in the form of insoluble zinc complex1. The extended availability of insulin from an insol-
uble zinc complex has been long known and utilized. The development of insulin sustained release formulations 
for injection originated from studies of the insulin solubility in acetate and phosphate buffer2. The studies found 
the efficiency of insulin precipitation to be a function of pH and zinc salt concentration. Recently, a similar 
approach was adopted with other peptide compounds in order to achieve their controlled and sustained release. 
A non-covalently bound adduct of glucagon-like peptide-1 (GLP-1) agonist with zinc acetate could prolong its 
terminal half-life t1/2 after subcutaneous application from 2 h to 8.5 h. It further reduced the initial burst release of 
GLP-1 from the formulation vehicle, indicating its potential for long term release3. A precipitation of recombinant 
Hirudin (rHir) by zinc salt at neutral pH was as well shown to result in Zn2+-rHir suspension with a prolonged 
biological activity in rats4. The prepared suspension was then further optimized with regards to pH and zinc salt5. 
Similarly, corticotrophin (ACTH) was precipitated with zinc salt6. The addition of zinc induced the dimerization 
of human growth hormone (hGH). The Zn2+-hGH dimer was more stable than the monomeric hGH form7,8. 
The formed structures of Zn2+-hGH were later found to be fibrils of amyloidogenic nature, able to release mon-
omers upon dilution9. Various studies have investigated short amyloidogenic peptides and their assemblies that 
mimic the amyloidosis process10–14. The amyloid structures have also been considered as a possible source for 
sustained release of small peptides, e.g. the GnRH analogue Leuprorelin (LHRH)15. In this connection, LHRH 
was complexed and precipitated with Zn2+, using sodium hydroxide (NaOH) solution for the pH adjustment. 
The lyophilizate was then incorporated into in situ forming implants16. The same technique for complexation and 
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precipitation was applied in another study with GnRH, tyroliberin (TRH), dalarelin and ACTH for the formation 
of Zn2+-peptide aqueous suspension17. Comparable to hGH, LHRH exhibited a similar tendency to form β-sheet 
rich aggregates with amyloid-like character15. In both cases, peptides with the ability to form amyloids were inves-
tigated. The amyloid structures are highly organized stable aggregates, which in most cases are associated with 
neurodegenerative diseases18. However, in the studies with hGH and LHRH, the concept of amyloids was applied 
to prepare complexes capable of slowly releasing the active peptide.
Based on the “amyloid concept” from these studies, we investigated whether a controlled pH shift in the pres-
ence of different concentrations of Zn2+ would lead to self-assembly and formation of nanostructures and fibrils 
of a synthetic D-Phenylalanine (Phe) form of GnRH peptide in vitro. The use of the synthetic form of GnRH 
aimed to achieve higher stability against degradation of the assembly19 (Fig. 1).
Results and Discussion
New approach to fibrillize and self-assemble GnRH [6-D-Phe] by Zn2+ and controlled pH shift. 
In the current study we applied two techniques for fibrillizing GnRH [6-D-Phe] and compared them to each other 
in order to select the most suitable one. The percentage of free GnRH [6-D-Phe] was analyzed by Reversed-Phase 
Chromatography (RP-HPLC).
The first technique was the method of choice used in earlier studies of precipitating LHRH, rHir, ACTH, 
TRH etc. and involved increasing the pH of the peptide solution containing Zn2+ from 7.2 to 8.2 by the addition 
of NaOH5,16,17,20. The GnRH [6-D-Phe] was complexed at 2.5 mg/mL from 5 mg/mL bulk concentration. Below 
pH 7.8 the percentage of precipitated GnRH [6-D-Phe] remained low at all Zn2+: GnRH [6-D-Phe] molar ratios 
and no correlation between molar ratio and pH could be obtained. Above pH 7.8, we observed an increase and a 
maximum of precipitated GnRH [6-D-Phe] of 95.9 ± 0.1% at a 10:1 Zn2+: GnRH [6-D-Phe] molar ratio (Fig. 2a; 
Supplementary Data and Information Table 1). The high percentage of precipitated peptide might be due to the 
interaction of the histidine (His) side chain with Zn2+ through its imidazole group. One major drawback of the 
technique is the unsatisfactory accuracy using the pH-adjustment with NaOH solution due to lack of buffer 
capacity at the pH value of interest. Thus upon addition of NaOH extremely unstable and high local pH values 
may result. This can lead on the one hand to the coinciding precipitation of Zn (OH)2 from a mixture of com-
plexed, free peptide and unbound Zn2+ and on the other to epimerization at the serine (Ser) of GnRH [6-D-Phe], 
preceding a Ser hydroxyl group triggered peptide bond hydrolysis21.
The second technique was based on a recent study of Valery et al., which showed that a change of pH value 
and thus deprotonation of the His residue in the GnRH agonist, TRH, could trigger a self-assembly of the peptide 
into nanotubes22. This pH dependent switch can be applied in the bottom-up development of pH-responsive 
nanomaterials as well as for the in vitro induced conformational change and fibrillation of GnRH [6-D-Phe]. In 
our study, this was achieved through a temperature controlled pH-shift between 7.2 and 8.2 with a Tris-buffered 
system, as an alternative to NaOH23.
The percentage of precipitated peptide reached 99.2 ± 0.2% at a 10:1 Zn2+: GnRH [6-D-Phe] ratio in 
0.05 M Tris buffer pH 7.8 after temperature reduction from 25 °C to 5 °C, over 24 h. In contrast, the precipita-
tion efficiency in a 0.05 M Tris buffer pH 7.2 reached only 36.2 ± 0.1% (Fig. 2b). This could be explained by the 
measured-temperature-induced pH increase of the Tris-buffered system with 0.03 pH units per 1 °C24. Cooling 
the Zn2+: GnRH [6-D-Phe] in Tris buffer (pH 7.8) from 25 °C to 5 °C promoted a pH increase from pH 7.3 to pH 
7.9. At this pH the His-side chain is in a deprotonated state and can form hydrogen bonds or enhance the peptide 
interaction with Zn2+ and the formation of an assembly. In contrast the solution of Zn2+: GnRH [6-D-Phe] in Tris 
buffer with pH 7.2 reached pH 7.3 at 5 °C (Supplementary Data and Information Table 2).
Figure 1. Overview of the in vitro GnRH [6-D-Phe] nanostructures and fibrils formation and evaluation.
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Existence of higher-order assembly of GnRH [6-D-Phe]. In order to study the conformational 
changes and secondary structures, resulting upon adding different molar concentrations of Zn2+ to GnRH 
[6-D-Phe], we used Attenuated Total Reflection Fourier Transform Infrared spectroscopy (ATR–FTIR). The 
bands at 1416 cm−1 and 1434–1454 cm−1 indicated an increase in the C-H bending and -C = O stretching vibra-
tion, respectively25–27 (Fig. 3a). Absorbance spectra analysis in the amide II range (1500–1600 cm−1) yielded two 
major peaks at ~1520 cm−1 and 1560 cm−1. The peak at 1560 cm−1 can be assigned to the N-H bend in plane and 
stretch. The peak at 1520 cm−1 has been associated in earlier studies with vibrations of heterocyclic compounds, 
e.g. furan ring, phenyl ring, imidazole ring and can be attributed to the stretching vibration of the –C=N bond 
in the imidazole heterocycle of the His side chain28–30 (Fig. 3a). The amide I region (1600–1700 cm−1) presented 
one major band at 1650 cm−1 as an indicator of an alpha-helical structure. The characteristic beta-sheet regions of 
Figure 2. Precipitated GnRH [6-D-Phe] from Zn2+: GnRH [6-D-Phe] solution. (a) With 0.6 N NaOH at 
pH > 7.8 and pH < 7.8 (b) in 0.05 M Tris buffer at 5 °C (starting pH at 25 °C given); the left panel illustrates an 
increased, but uncontrolled, precipitation at molar ratio Zn2+: GnRH [6-D-Phe] 10:1 at pH > 7.8 with 0.6 N 
NaOH; the right panel illustrates a new method of a temperature controlled Tris buffer precipitation of Zn2+: 
GnRH [6-D-Phe] 10:1 at 5 °C.
Figure 3. FT-IR Spectra of the Zn2+: GnRH [6-D-Phe] assemblies in comparison to GnRH [6-D-Phe]. (a) 
normalized, absorbance spectra (b) normalized second derivative of the absorbance spectra.
www.nature.com/scientificreports/
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1610–1630 cm−1 and 1680–1700 cm−1 were visibly overlapped from the major alpha-helical peak. A deconvolu-
tion of the absorbance spectra could unveil a beta-sheet peak in the 1604–1617 cm−1 range (Supplementary Data 
and Information Fig. 2). With increasing Zn2+ molar concentrations, most stunning appears to be the change 
in the percentage of beta-sheet and carbonyl stretching area. The observed changes are good indicators of the 
initiation of oligomer formation at 4:1 and the maximum stretching of the carbonyl group at 10:1 Zn2+: GnRH 
[6-D-Phe] molar ratios (Fig. 3a, Table 1). With higher Zn2+ concentrations the beta-sheet peak disappeared 
and an increase of the carbonyl stretching due to the formation of ZnO/Zn (OH)2 resulted. Its strong peak at 
1560 cm−1 coincides with the peptide amide II region. Analysis of the second-derivative amide I region showed 
bands at ~1611 cm−1 and at ~1690 cm−1, typical for oligomers in solution31–36 (Fig. 3b). This supports the hypoth-
esis that the oligomeric structure of GnRH [6-D-Phe] forms with increasing molar concentration of Zn2+.
Binding of Zn2+ to GnRH [6-D-Phe]. The LHRH interactions with Zn2+, Ni2+ and Cu2+ were studied in 
the 1980s17,20. The results of the 1H-NMR spectroscopy favored a view that the coordination between Zn2+ and 
LHRH takes place at the carbonyl oxygen of the His-Trp peptide bond20. In addition, the imidazole of the His 
residue coordinates to the Zn2+ ligand. This coordination to Zn2+ happens in a fast proton exchange. The changes 
of the chemical shift in the aromatic part of the 1H-NMR in correlation to the added molar concentration of Zn2+ 
can be traced back to two distinct occurrences. The first one involves the already mentioned His and Trp residue 
interaction with Zn2+ (Supplementary Data and Information Fig. 1). The second one can be due to a stronger 
peptide-peptide interaction37,38. Using the observed change in the chemical shift (Δδ), we fitted the data to a 
hyperbolic function with the following equation:
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This allowed us to determine the dissociation constants (Kd) of the Zn2+: GnRH [6-D-Phe] assembly, assum-
ing a 1:1 stoichiometry. The calculated value of the dissociation constant Kd (38.4 ± 4.8 mM1) indicated a weak 
interaction between Zn2+ and GnRH [6-D-Phe]. The Zn2+ ligand concentration for the interaction with GnRH 
[6-D-Phe] was in the range of 4–160 mM (Fig. 4).
Zn2+: GnRH [6-D-Phe] assembly: nanostructures and fibrils. In order to visualize the formation pro-
cess of the assembly, we took atomic force microscopy (AFM) images in solution and in dry state at the highest 
precipitation efficiency, Zn2+: GnRH [6-D-Phe] 10:1. The observed fast proton exchange and interaction in the 
1H-NMR spectra required the use of a D2O: DMSO-d6 (80:20) solvent in order to capture the images. In solution, 
nanostructures with a diameter of up to 5 nm in the presence of Zn2+ were recorded (Fig. 5a,b; Supplementary 
Data and Information Fig. 3). The assembly process appeared to be dynamic and going through different stages: 
immediately after preparation large circular aggregates formed (Fig. 5a), which resulted after 48 h in 5 nm nano-
structures (Fig. 5b). The smaller size oligomers might be due to solvation of peptide chains from the preliminary 
formed large aggregate back into solution. In dry state, Zn2+: GnRH [6-D-Phe] small fibrils with a diameter of up 
to 10 nm were observed (Fig. 5c,d).
The effect of increasing Zn2+ ion concentration on GnRH [6-D-Phe] fibrillization was further studied with 
Thioflavin T (ThT) assay. ThT is a benzothiazole dye used to visualize and quantify misfolded protein fibrils or 
amyloid both in vitro and in vivo39. The assay could show the formation of secondary structures with increasing 
Zn2+ concentration. Above a 10:1 Zn2+: GnRH [6-D-Phe] ratio, the obtained fluorescence values decreased. Pure 
GnRH [6-D-Phe] and aggregated Aβ42 were included and served as negative and positive control, respectively 
(Table 2).
Main peaks cm−1 (% Area)
-C-H bending and C=O 
stretching
-C=N 
(Imidazole) Amide II Beta-sheet Amide I
GnRH [6-D-Phe]
1416 (2%)
1434 (2%)
1454 (6%)
1514 (3%) 1568 (27%) 1612 (6%) 1652 (54%)
Zn2+: GnRH [6-D-Phe] 2_1
1414 (4%)
1435 (5%)
1456 (7%)
1514 (2%) 1563 (17%) 1608 (10%) 1653 (54%)
Zn2+: GnRH [6-D-Phe] 4_1
1417 (8%)
1435 (1%)
1452 (8%)
1515 (3%) 1560 (20%) 1617 (20%) 1657 (40%)
Zn2+: GnRH [6-D-Phe] 10_1
1416 (13%)
1435 (1%)
1450 (7%)
1517 (4%) 1561 (32%) 1604 (9%) 1653 (35%)
Zn2+: GnRH [6-D-Phe] 20_1 1415 (20%)1447 (5%) — 1560 (40%) — 1653 (15%)
Table 1. Main peaks and integrated peak area in the deconvoluted normalized absorbance spectra of Zn2+: 
GnRH [6-D-Phe] assemblies in comparison to GnRH [6-D-Phe].
www.nature.com/scientificreports/
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Molecular dynamics simulation of Zn2+: GnRH [6-D-Phe] 10:1 assembly. Using molecular dynam-
ics (MD) simulations, we further explored the interaction between Zn2+ and GnRH [6-D-Phe] in the 10:1 ratio. 
Analysis of the trajectory with the linear interaction energy method showed three dimerization events driven by 
VdW and electrostatic interactions in the Zn2+: GnRH [6-D-Phe] 10:1 (Supplementary Data and Information 
Figure 4. NMR shift in solution-state NMR spectra vs. Zn2+ concentration for the determination of the 
dissociation constant Kd of the Zn2+: GnRH [6-D-Phe] 1:1 stoichiometry.
Figure 5. AFM image of the Zn2+: GnRH [6-D-Phe] 10:1 complex. (a,b) Oligomers after preparation with 
tapping mode in Tris buffer solution (c,d) fibrils with tapping mode in air (z-scale indicates the average size of 
the formed oligomers and fibrils).
www.nature.com/scientificreports/
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Fig. 4). These interactions could further confirm the observed weak coordination of Zn2+ to GnRH [6-D-Phe] in 
the 1H-NMR spectra40,41. In the first dimerization event, the Arg8 residue of peptide 1 was engulfed by the second 
peptide. The dimer’s interface consists of Leu7, Arg8 and Pro9 of peptide 1 and pGlu1, Ser4, Pro9, Gly-NH210 
of peptide 2 (Fig. 6a). The second and third dimerization events present a flatter interface, which is composed of 
residues pGlu1, His2 Tyr5 D-Phe6 Pro9 of peptide 1 and Trp3 Ser4 Tyr5 of peptide 2 (Fig. 6b). During the first 
dimerization event there was a pronounced conformational change of peptide 1, reflected from the RMSD val-
ues (Fig. 6c,d). A cluster analysis showed that the dimer formed in the first dimerization event (at around 10000 
frames) is the most prominent species in the course of the simulation. MD simulations showed that the dimer 
formation is furthermore driven by hydrogen bond formation between the peptide residues (Supplementary Data 
and Information Fig. 5).
Self-assembled Zn2+: GnRH [6-D-Phe] 10:1 as platform for sustained GnRH [6-D-Phe] delivery 
in the form of oil depot formulation. In order to generate a GnRH-depot system two new approaches 
were evaluated. In the first setup, the nanostructure/fibril formation of GnRH [6-D-Phe] in the presence of Zn2+ 
was directly performed in the freezing phase of a lyophilization process. The temperature-dependent pH switch 
of the Tris buffer system led to the Zn2+ induced self-assembly of GnRH [6-D-Phe], simultaneously stabilized 
in a 3D freeze-dried matrix (Fig. 7). The complex was then incorporated in medium chain triglycerides (MCT) 
+3% (w/w) aluminium distearate (AlSt) +1% (w/w) phospholipon 90 H (PL 90 H) +5% (w/w) kolliphor ELP 
(KP ELP) or in castor oil: MCT 50:50% (w/w) oil vehicle. For the second in situ method, the Tris buffer salt was 
ThT Fluorescence [a.u.] ± SD
0 h 1 h 3 h 5 h 24 h
GnRH [6-D-Phe] 1.1 ± 5.6E-03 1.2 ± 2.8E-03 1.2 ± 1.8E-03 1.1 ± 4.6E-03 1.1 ± 2.1E-03
2:1 5.7 ± 8.7E-03 5.6 ± 2.5E-02 5.3 ± 1.6E-02 6.4 ± 5.9E-02 5.8 ± 1.6E-02
4:1 7.9 ± 1.3E-02 6.3 ± 2.0E-02 7.3 ± 9.2E-03 5.6 ± 3.4E-02 5.8 ± 1.7E-02
10:1 2.5 ± 6.3E-03 2.8 ± 4.1E-03 3.3 ± 3.9E-02 4.9 ± 4.1E-02 2.4 ± 8.6E-03
20:1 1.2 ± 3.1E-03 1.0 ± 5.2E-03 1.2 ± 7.7E-03 1.1 ± 9.4E-03 1.0 ± 7.4E-03
Aβ 42 5.1 ± 1.8E-02 3.9 ± 1.1E-02 5.9 ± 1.2E-01 4.7 ± 1.9E-01 4.7 ± 1.9E-01
Table 2. ThT fluorescence recorded over 24 h of the Zn2+: GnRH [6-D-Phe] assemblies in comparison to GnRH 
[6-D-Phe] and Aβ 42.
Figure 6. MD simulation. (a,b) Dimer structures of GnRH [6-D-Phe]-1 in blue, GnRH [6-D-Phe]-2 in yellow, 
Zn2+ in black, interfacial residues pictured as VdW spheres (c,d) RMSD value peptide 1 and RMSD value 
peptide 2.
www.nature.com/scientificreports/
7SCieNTifiC RepoRtS |  (2018) 8:11280  | DOI:10.1038/s41598-018-29529-w
added to the oil vehicle separately from GnRH [6-D-Phe], enabling a possible precipitation and fibrils formations 
as dissolution of both suspended water soluble compounds takes place after in vivo application. Both Zn2+: GnRH 
[6-D-Phe] complexes were characterized and evaluated by an in vitro release study.
The in vitro release of GnRH [6-D-Phe] from the in situ complex with Zn2+ in the oil vehicle OV1: MCT +3% 
(w/w) AlSt +1% (w/w) PL 90 H +5% (w/w) KP ELP or OV2: castor oil: MCT 50:50% (w/w) reached a maximum 
of 40% after 2–3 days (Fig. 8). In contrast, the preformed complex formulations in OV1 and OV2 showed slow 
and continuous in vitro release profiles over 14 days with a minor burst effect. The release from the reference for-
mulation based on pure GnRH [6-D-Phe] in castor oil: MCT 50:50% (w/w) was fast and almost complete within 
24 h. In contrast the release was more sustained over 4 days from MCT +3% (w/w) AlSt +1% (w/w) PL 90 H +5% 
(w/w) KP ELP.
In order to determine the release kinetics from the Zn2+: GnRH [6-D-Phe] formulations, the data was fitted 
to first-order, Higuchi, zero-order and Korsemeyer-Peppas models42. The formulations clearly did not follow zero 
order release kinetics (Fig. 9). The model that best fitted the release data was evaluated by correlation coefficient 
Figure 7. Zn2+: GnRH [6-D-Phe] complex and oil depot suspension preparation.
Figure 8. In vitro release profiles Zn2+: GnRH [6-D-Phe] and GnRH [6-D-Phe] oil depot formulations.
www.nature.com/scientificreports/
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(R2) (Table 3). The release profile of the preformed complex formulation in OV1 could be best explained by 
Higuchi model, as the plot showed linearity with R2 value of 0.9416. The Korsmeyer-Peppas plots of all formula-
tions showed fair linearity (R2 values between 0.95–0.97) with a considerably high slope value (n). This indicated 
a coupling of diffusion and erosion mechanisms or so called anomalous diffusion43.
Compared to the reference formulations without Zn2+, the release profiles of the complex and in situ complex 
formulations were not influenced by the oil matrix. Thus the interaction of Zn2+ with GnRH [6-D-Phe] in a pre-
formed lyophilized complex could accomplish a superior controlled release of GnRH [6-D-Phe] with minor burst 
effect. It represents a simple and scalable formulation approach.
Conclusion
As illustrated above a short synthetic decapeptide, GnRH [6-D-Phe] can form nanostructures and fibrils in vitro 
through the addition of Zn2+ ions. The aggregation tendency seems to depend on Zn2+ concentration, reaching 
a maximum efficiency of almost 100% at a 10:1 Zn2+: GnRH [6-D-Phe] ratio. The oligomerization and mature 
fibrils formation of GnRH [6-D-Phe] are Zn2+ induced. GnRH [6-D-Phe] fibrils form in a Tris-buffered pH 
Figure 9. Linear fit of in vitro release kinetic values of GnRH [6-D-Phe] from selected Zn2+: GnRH [6-D-Phe] 
and GnRH [6-D-Phe] oil depot formulations. (a) 1First-order equation, log Q = Log Q0 −kt/2.303; (b) 2Higuchi 
equation, Q = kt½; (c) 3Zero-order equation, Q = Q + kt; (d) 4Korsmeyer-Peppas equation, Qt/Qµ = ktn.
Formulation
First-
ordera R2 Higuchib R2
Zero-
orderc R2
Korsmeyer-
Peppasd R2 n
10:1_complex_OV1 0.8574 0.9416 0.7589 0.9784 24.342
10:1_complex_OV2 0.8214 0.8848 0.7087 0.9296 18.314
10:1_in situ complex_OV1 0.5505 0.7552 0.5092 0.9533 16.491
10:1_in situ complex_OV2 0.6654 0.7891 0.5836 0.8960 13.566
GnRH [6-D-Phe]_OV1 0.5405 0.7460 0.4949 0.9471 27.433
GnRH [6-D-Phe]_OV2 0.0721 0.2894 0.1229 0.5010 19.913
Table 3. In vitro release kinetic values of GnRH [6-D-Phe] from selected Zn2+: GnRH [6-D-Phe] oil depot 
formulations. aFirst-order equation, log Q = Log Q0 − kt/2.303; bHiguchi equation, Q = kt½; cZero-order 
equation, Q = Q + kt; dKorsmeyer-Peppas equation, Qt/Qµ = ktn.
www.nature.com/scientificreports/
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7.8–8.2 environment in a controlled manner through temperature reduction and a pH shift. The in vitro release 
of the GnRH [6-D-Phe] peptide from the freeze-dried assembly was sustained and continuous over 14 days and 
can be viewed as a promising platform for the controlled delivery of peptides.
Recent articles have highlighted the numerous fields of application of similar self-assembled peptide –based 
nanostructures44–46. The further investigation of the GnRH [6-D-Phe]: Zn2+ self-assembling/oligomerization pro-
cess is necessary as to evaluate to what extent it can find application in other research fields.
Materials and Methods
Gonadorelin [6-D-Phe] acetate peptide (pE1–H2–W3–S4–Y5–(D) F6–L7–R8–P9–G10–NH2) 
or(pGlu-His-Trp-Ser-Tyr-D-Phe-Leu-Arg-Pro-Gly-NH2) was provided by BFC Biopept-Feinchemie asly-
ophilized powder and acetate salt (purity 99.76%, water content 6.73% and acetate peptide ratio (MW/MW) 1.8). 
Amyloid β-Protein ( 1- 42) ( H- As p- Al a- Gl u- Ph e- Ar g- Hi s- As p- Se r- Gl y- Ty r- Gl u- Va l- Hi s- Hi s- Gl n- Ly s- Le u- Va l- Ph 
 e- Ph e- Al a- Gl u- As p- Va l- Gl y- Se r- As n- Ly s- Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala-OH) 
was provided by Bachem Holding AG as lyophilizied powder. Gelling agents: Aluminiumdistearte (Alugel 30 
®HEP), Baerlocher, D-Unterschleissheim); Wetting agents: phospholipon 90 H (Sigma Aldrich, D- Taufkirchen); 
Resuspendibility enhancer: Kolliphor ELP (BTC Europe, D-Burgbergheim); Complexing agent: Zinc acetate 
dihydrate (Zn (CH3COO−)2 Merck KGaA, D-Darmstadt); Oil vehicle: miglyol 812 (MCT) (Caesar & Loretz, 
D-Hilden), castor oil (Gustav Heess, D-Leonberg).
Formation of the Zn2+: GnRH [6-D-Phe] assembly with 0.6 N NaOH. Equal amounts of 4 mM 
GnRH [6-D-Phe] and 16 mM, 40 mM, 60 mM, 80 mM, 120 mM, 160 mM, 200 mM and 240 mM Zn(CH3COO−)2 
aqueous solutions were combined. The pH adjustment was performed using a 0.6 N NaOH under stirring care-
fully with a dropwise addition along the side wall. The formed precipitate was centrifuged at 12000 × g for 10 min, 
washed with highly purified water. GnRH [6-D-Phe] in the supernatant as well as in the precipitate was analyzed 
through a Reversed Phase Chromatography (RP-HPLC) (Supplementary Data and Information Table 1).
Formation of the Zn2+: GnRH [6-D-Phe] assembly in Tris buffer. Equal amounts of 4 mM GnRH 
[6-D-Phe] and 40 mM, 60 mM, 200 mM Zn(CH3COO−)2 solution in 0.05 M Tris buffer (pH = 7.2, 7.4, 7.6, 7.8, 
8.2) were combined. Precipitation was performed at reduced temperature, 5 °C. The formed precipitate was cen-
trifuged at 12000 × g for 10 min, washed with highly purified water. GnRH [6-D-Phe] in the supernatant as well 
as in the precipitate was analyzed through a RP-HPLC (Supplementary Data and Information Table 2).
ATR-FTIR. Equal amounts of 4 mM GnRH [6-D-Phe] and 8 mM, 16 mM, 40 mM, 80 mM Zn(CH3COO−)2 
solution in a 0.05 M Tris buffer (pH 7.8) were combined. Aliquots of 30 µl of each prepared solution were loaded 
and the spectra were recorded with a Tensor 27 FTIR spectrometer (Bruker Optics, Ettlingen, Germany) using a 
Bio-ATR unit at 20 °C. Corresponding blank spectra were subtracted. Spectra were recorded at 4 cm−1 resolution 
and the second derivative spectrum was generated (OPUS, Bruker Optics, Ettlingen, Germany).The spectra data 
analysis and Fourier Self-Deconvolution (FSD) was performed with Origin 2018 software. FSD was performed 
using bandwidth of 10 cm−1 and noise suppression factor of 0.3. The structure content of the deconvoluted peaks 
was determined using Gaussian band shapes by an iterative curve fitting.
NMR Spectroscopy. Solution 1H-NMR zinc titration of the peptide in D2O: DMSO-d6 (80:20) solvent was 
performed in a 0.05 M Tris buffer (pH 7.8) at 25 °C on a Bruker Avance III HD 800 MHz and at a reduced temper-
ature 5 °C on a Varian NMR System 400 MHz. The binding efficiency of Zn2+ to peptide was determined through 
the NMR analysis of the Zn2+: GnRH [6-D-Phe] assemblies. The spectra were evaluated using the MestReNova 
Software 10.0.2-15465 (Supplementary Data and Information Fig. 1).
Atomic force microscopy (tapping in Air). The 10:1 Zn2+: GnRH [6-D-Phe] (20 ng/µL; 20 µL volume) 
was deposed onto poly-L-lysine coated mica for 2 min, followed by gentle rinsing with water and dried in a N2-gas 
stream. Coating the mica with (+) charged poly-L-lysine repulsed the (+) charged arginine peptide residues of 
chains not involved in the dimerization process, allowing better imaging. AFM imaging was performed on a 
Multimode AFM, equipped with a Nanoscope III controller and a type E scanner. Images were recorded on dried 
samples, under ambient conditions, and using Silicon cantilevers (Olympus; AC160TS; resonance frequency 
≈300 kHz). Typical scans were recorded at 1–3 Hz line frequency, with optimized feedback parameters and at 
512 × 512 pixels. For image processing and analysis, Scanning Probe Image Processor (v6.4; Image Metrology) 
was employed. Image processing involved background correction using global fitting with a third-order polyno-
mial and line-by-line correction through the histogram alignment routine.
Atomic force microscopy (tapping in Tris buffer solution). The AFM images were performed using 
the AFM NanoWizard® 4 from JPK Instruments with SPM software and an integrated Axiovert 200 inverted 
microscope from Zeiss. As cantilever the qp-BioAC CB3 (Nanosenors; resonance frequency ≈30 kHz) was used. 
A mica-chip was glued on a microscope slide and 20 µl of the 10:1 Zn2+: GnRH [6-D-Phe] was added. After 5 min 
incubation time, the mica-substrate was washed with Tris buffer. The imaging was performed in 1 ml Tris buffer 
and with the tapping mode (QI™ Advanced Imaging). The following values have been set: Z-length 50–70 nm; 
duration 2 ms and pixel size 256 × 256. All images were processed and optimized with Data Processing Software 
from JPK. The processing involved removing incorrect lines, replacing outlier pixel values with the median value 
of neighbouring pixels and line-by-line correction with a first-order polynomial fit. A histogram is calculated for 
each line and only the data between the lower and upper limits is used for fitting the polynomial.
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Thioflavin-T Binding Assay. The fluorescence intensity was measured in multi-well plates in an Agilent 
Cary Eclipse Fluorescence Spectrophotometer (exc.at 440 nm (slit width 5 nm), em. at 482 nm (slit width 10 nm), 
and averaging over 60 s). 100 µl of each Zn2+: GnRH [6-D-Phe] sample, prepared in 0.05 M Tris buffer pH 7.8 
containing 20% DMSO, was vortexed gently and mixed with 200 µL 50 µM ThT solution prepared in the same 
buffer and stored at 5 °C. Aβ42 lyophilizate was dissolved in 0.05 M Tris pH 7.8 containing 20% DMSO and stored 
at 5 °C over 24 h for the purpose of forming minimal peptide aggregation. 100 µl of 150 µM Aβ42 and 100 µl of 
4 mM GnRH [6-D-Phe] were used as controls and treated the same way as the Zn2+: GnRH [6-D-Phe] samples. 
The fluorescence intensity of all samples was measured over 24 hours.
MD simulations. Molecular dynamic simulations were performed using the Amber 16 suite47. Non-standard 
residue files were generated using antechamber and the peptide structure was generated with t-leap. Two identical 
GnRH [6-D-Phe] molecules and 20 zinc ions were placed at random coordinates in a TIP3P water box using 10 Å 
of padding. Energy minimization was performed with pmemd. MPI with the steepest descent method for 5000 
cycles and with the conjugate gradient method at constant volume for the remaining 45000 cycles. The system was 
then heated from 0 to 300 K and equilibrated for 200 ps with pmemd.cuda. A Langevin thermostat with a collision 
frequency set to 5 ps−1 was used. Pressure was kept constant using isotropic position scaling and a Monte Carlo 
barostat. The SHAKE algorithm was turned on. After equilibration, a 500 ns production run was performed with 
the same thermostat and barostat settings as during equilibration. VdW and electrostatic interaction energies 
were calculated using the LIE method as implemented in cpptraj and plotted with matplotlib40,41,48.
Zn2+: GnRH [6-D-Phe] complex preparation. Zn2+: GnRH [6-D-Phe] 10:1 preformed complex was pre-
pared from equal amounts of 4 mM GnRH [6-D-Phe] and 40 mM Zn(CH3COO−)2 in 0.05 M Tris buffer pH 7.8. 
The pH of the resulting mixture at 25 °C was 7.2. The temperature was then reduced to 5 °C and resulted in a pH 
increase to pH 7.8. The mixture was kept at 5 °C for 24 h and then freeze dried. The in situ Zn2+: GnRH [6-D-Phe] 
10:1 complex was prepared from equal amounts of 4 mM GnRH [6-D-Phe] and 40 mM Zn (CH3COO−)2 in 
water. The pH of the resulting mixture at 25 °C was 6.5. Similarly to the preformed complex the temperature was 
reduced to 5 °C. The pH stayed constant. The mixture was kept at the same conditions as the preformed complex 
and freeze dried. Both complexes were freeze dried using a Christ Epsilon 2–6 D freeze-dryer (Martin Christ 
Gefriertrocknungsanlagen GmbH, D-Osterode) (150 mTorr; primary drying: 60 h, −20 °C; secondary drying: 
18 h, 20 °C) with process and plant control LPC plus SCADA software.
Zn2+: GnRH [6-D-Phe] lyophilisate micronization. The dry- cryogenic micronization of Zn2+: GnRH 
[6-D-Phe] lyophilisate and the separately added tris buffer were performed using a Retsch Cryo Mill (Retsch 
Technology, Haan, Germany). The grinding process was performed for the duration of 1 min at 25 Hz with a 
precooling phase of 10 min in liquid nitrogen.
Zn2+: GnRH [6-D-Phe] oil depot preparation. The Zn2+: GnRH [6-D-Phe] oil depot formulations prepa-
ration was performed under a laminar flow cabinet in a two-step process. The gelling agent Aluminiumdistearte 
Alugel 30 ®HEP (AlSt) was weighed and suspended in the oil vehicle miglyol 812 (MCT) to a final weight of 95 g 
(corresponding to 100 mL). The prepared mixture was heated at 174 °C for 2 hours under N2. After cooling down 
to 25 °C the wetting agent, Phospholipon 90 H (PL 90 H), and the resuspendibility enhancer, Kolliphor ELP (KL 
ELP), were incorporated into the gelled oil matrix and stirred at 160 °C for 1 hour under N2. The castor oil: MCT 
50:50% (w/w) matrix was heated and agitated under inert atmosphere (N2) at 60 °C and then cooled down to 
room temperature at 25 °C. The cryo-ground Zn2+: GnRH [6-D-Phe] lyophilizate was suspended in the prepared 
oil matrices at ambient temperature of 25 °C using an Ultra-Turrax T-10 basic (IKA Labortechnik, Germany) 
for 5 minutes at 2000 rpm. 139.8 mg of Tris buffer salt consisting of 2.01 g Trizma HCl and 1.485 g Trizma Base 
was added to the in-situ complex formulation. The 5 mg/mL Zn2+: GnRH [6-D-Phe] oil depot suspensions were 
aliquoted in 20 R glass vials. The prepared suspensions were stored at 2–8 °C.
GnRH [6-D-Phe] extraction from the complex and oil matrix. In order to establish a suitable extrac-
tion method for the determination of the GnRH [6-D-Phe] content in the oil depot suspension the following 
extraction experiments were performed. The GnRH [6-D-Phe] was extracted from the prepared Zn2+: GnRH 
[6-D-Phe] oil depot suspensions using dichloromethane (DCM), where GnRH [6-D-Phe] is not soluble in com-
bination with HEPES (pH 7.4). HEPES was selected as medium instead of PBS buffer, since phosphate can precip-
itate the zinc salt from the complex. 2 mL oil depot suspension was weighted into a falcon tube, 4 mL DCM and 
6 mL HEPES (pH 7.4) were added. The tube was shaken or vortexed at room temperature (25 °C) and put into an 
incubated shaker 3031 (GFL, Germany) at 39 °C and 60 rpm for 48 h. The RP-HPLC analysis was performed at 
220 nm. A second extraction method was applied: 2 ml of each formulation were pipetted into 6 ml HEPES (pH 
7.4). The falcon tubes were placed in an incubated shaker 3031 (GFL, Germany) at 39 °C and 60 rpm for 48 h. The 
tubes were then centrifuged for 60 minutes at 4000 rpm and 5 °C. 1 ml of the lower aqueous phase was used for 
RP-HPLC at 220 nm. The second extraction with HEPES (pH 7.4) delivered results of nearly 100% and indicated 
high extraction efficiency.
In vitro release study. The in vitro release study was conducted using VISKING® dialysis tubing, MWCO 
12–14 kD, RC, 28 mm (SERVA, Germany). The tubes were filled with 1.5 mL formulation. The release medium 
was 20 mL HEPES (pH 7.4). HEPES was selected as release medium instead of PBS buffer, since phosphate can 
precipitate the zinc salt from the complex. The in vitro evaluation was performed in duplicates and in an incu-
bated shaker 3031 (GFL, Germany) at 39 °C and 60 rpm. 1 mL sample was used for the RP-HPLC analysis at the 
following time points: 1 h, 3 h, 5 h, 7 h, 22 h, 25 h, 28 h, 46 h, 52 h, 76 h, 100 h, 172 h, 196 h, 220 h, and 336 h (14 
days). The GnRH [6-D-Phe] content in the oil vehicle and in the donor cell was extracted using 2 mL HEPES 
www.nature.com/scientificreports/
1 1SCieNTifiC RepoRtS |  (2018) 8:11280  | DOI:10.1038/s41598-018-29529-w
buffer (pH 7.4). After 48 hours of an equilibration of the peptide between the two phases the emulsion was centri-
fuged for 60 minutes at 4000 rpm and 5 °C. The quantity of the peptide in the lower aqueous phase was analysed 
by RP-HPLC at 220 nm.
Determination of the GnRH [6-D-Phe] (RP-HPLC). The GnRH [6-D-Phe] content in the formed pre-
cipitate/fibrils was analysed by RP-HPLC after dissolution in 0.1% acetic acid, using a LUNA C8 (4.6 × 250 mm; 
size = 5 µm; Phenomenex, USA) column, with a C8 pre-column (4 × 3 mm; size = 5 µm) at an HPLC Agilent 
1100/1200 series (Agilent Technologies, USA) (mobile phase A (water +1 mL/L Trifluoroacetic acid (TFA) (v/v)) 
and mobile phase B (800 g Acetonitrile +200 g water +1.2 mL TFA), 1.1 mL/min flow, column temperature 40 °C, 
and autosampler temperature 2–8 °C. The Retention Time (RT) of GnRH [6-D-Phe] was 8.5 ± 1.5 minutes with 
UV detection at 220 nm.
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